AstraZeneca (AZN) Stock News

Berenberg analysts say AstraZeneca's new hypophosphatasia drug efzimfotase alfa can replace and expand the $2B Strensiq franchise. They raise peak sales estimate to $4.2B from $3B, citing a superior profile and significant unmet need in both pediatric and adult patients. Shares fell 1.6%.

AstraZeneca will pay Insitro $40 million upfront and up to $1.46 billion in milestones for exclusive worldwide rights to AI-identified drug programs. The partnership targets fatty liver disease and cardiomyopathies. Insitro uses its AI platform to find disease root causes. AstraZeneca handles clinical development and commercialization.

Peak sales of AstraZeneca's Efzimfotase Alfa could hit $3 billion, but only if the drug secures a narrow approval, according to the company's unit chief.

AstraZeneca's biopharma president Ruud Dobber expressed confidence in the unit's growth prospects, citing upcoming drug launches and pivotal studies. The division faces headwinds from Farxiga's patent loss and the Wainua trial failure but remains on track for the 2030 revenue target.

AstraZeneca's biopharma head said the company constantly monitors deal opportunities, suggesting ongoing M&A interest.

The biopharma division head at AstraZeneca said the company is progressing toward its 2030 revenue target.

Broker comments on UK stocks: Pennon's rights issue lifts asset concerns, Shell's trading update positive, AstraZeneca pipeline strong, Unilever sales growth expected to slow, and more.

Bernstein analysts say AstraZeneca's strong R&D pipeline and breadth make a prolonged downturn like Roche's 2022-2025 experience unlikely. They trim target to 198 pounds from 200 pounds. Shares up 1% to 120.80 pounds.

AstraZeneca will purchase $2 billion in convertible preferred shares of Summit Therapeutics at $18.36 per share, a 10% premium. The companies also agreed to collaborate on clinical trials combining ivonescimab with AstraZeneca's ADC portfolio.

AstraZeneca shares gained 1.23% to GBP125.52 on Friday, outpacing the FTSE 100's 0.14% rise. The stock remains 20.21% below its 52-week high of GBP157.32. Trading volume of 1.5 million shares was below the 50-day average of 3.6 million.

AstraZeneca's sBLA for IMFINZI plus enfortumab vedotin in muscle-invasive bladder cancer has been accepted and granted Priority Review by the FDA. The decision is based on the VOLGA Phase III trial showing statistically significant improvements in event-free survival and overall survival. The PDUFA date is Q4 2026.

AstraZeneca's regulatory filings for IMFINZI plus enfortumab vedotin are currently being reviewed in the EU, Japan, and other countries, following the FDA Priority Review.

AstraZeneca announced the FDA accepted its supplemental application for IMFINZI plus enfortumab vedotin in muscle-invasive bladder cancer. The application received Priority Review, with a PDUFA date in Q4 2026, based on the VOLGA Phase III trial showing statistically significant improvements in event-free and overall survival.

AstraZeneca said its upgraded production base in Wuxi, China is scheduled to become operational in the fourth quarter of 2029.

AstraZeneca plans a roughly 200 million yuan investment to modernize its Wuxi manufacturing site in China.

AstraZeneca's breast-cancer drug missed its primary endpoint in a late-stage study. The failure lifts questions about the company's oncology pipeline and could pressure the stock near term.

The SERENA-4 trial of AstraZeneca's etcamah combination therapy failed its primary endpoint with no new safety signals. The miss may pressure the breast cancer franchise and stock over the near term.

RBC initiates AstraZeneca coverage at Outperform, target 14,500p.

Tozorakimab 300mg reduced moderate/severe COPD exacerbations by 29% in the TITANIA trial, including current and former smokers. Positive read for AstraZeneca's respiratory pipeline but source is unconfirmed.

AstraZeneca confirmed that its other phase III trials for volrustomig are proceeding as planned. No further details were disclosed.